Ryvu Therapeutics to Present Preclinical RVU602 and ONCO Prime Data
Ryvu Therapeutics says it will present preclinical data on RVU602, a novel ADC payload, and its ONCO Prime platform at the 2026 EORTC-NCI-AACR Symposium.
Ryvu Therapeutics says it will present preclinical data on RVU602, a novel ADC payload, and its ONCO Prime platform at the 2026 EORTC-NCI-AACR Symposium.